Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019025847) TREATMENT REGIMENS
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/025847 International Application No.: PCT/IB2017/095002
Publication Date: 07.02.2019 International Filing Date: 30.11.2017
IPC:
A61K 39/395 (2006.01) ,C07K 16/28 (2006.01) ,A61P 7/00 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
28
against receptors, cell surface antigens or cell surface determinants
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
7
Drugs for disorders of the blood or the extracellular fluid
Applicants:
NOVARTIS AG [CH/CH]; Lichtstrasse 35 4056 Basel, CH
Inventors:
ROLLINS, Scott; US
ROTHER, Russell; US
STOCKER, Jonathan; US
BRUEDERLE, Andreas; CH
Priority Data:
62/541,13304.08.2017US
Title (EN) TREATMENT REGIMENS
(FR) SCHÉMAS DE TRAITEMENT
Abstract:
(EN) The present invention relates to the treatment or prevention of P-selectin mediated disorders, and to anti-P-selectin antibodies or binding fragments thereof, for use in the treatment or prevention of such disorders. In particular, the invention relates to the treatment or prevention of pain crises associated with sickle cell disease, and to anti-P-selectin antibodies or binding fragments thereof, for use in the treatment or prevention of pain crises associated with sickle cell disease.
(FR) La présente invention concerne le traitement ou la prévention de troubles médiés par la P-sélectine, et des anticorps anti-P-sélectine ou des fragments de liaison de ceux-ci, pour une utilisation dans le traitement ou la prévention de tels troubles. En particulier, l'invention concerne le traitement ou la prévention de crises douloureuses associées à la drépanocytose, et des anticorps anti-P-sélectine ou des fragments de liaison de ceux-ci, pour une utilisation dans le traitement ou la prévention des crises douloureuses associées à la drépanocytose.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)